Innovative Platform Navigo Proteins specializes in novel scaffold proteins-based affinity ligands, offering highly engineerable and selective solutions for biologics purification and biopharmaceutical applications. This distinct platform presents multiple opportunities to supply custom affinity ligands and GMP-compliant resins to biopharma companies seeking tailored separation solutions.

Strategic Partnerships Recent collaborations with organizations like SCK CEN, VERAXA, and Nostrum Biodiscovery demonstrate Navigo's active engagement in radiotheranostics, click chemistry, and computational molecular engineering. These alliances indicate potential sales avenues within advanced biopharma development, radiopharmaceuticals, and innovative tagging technologies.

Product Diversification The company has launched and developed a range of affinity resins, including COVID-19 spike protein affinity resin and targeting ligands for specific fusion proteins. This product diversification allows opportunities to serve vaccine manufacturers, biopharmaceuticals, and diagnostic firms with highly specific purification and targeting solutions.

Growing Industry Demand Navigo’s capabilities align with increasing market needs for bespoke bioprocessing tools and targeted therapies, especially in biologics manufacturing, vaccine development, and theranostic applications. These sectors offer high-volume sales potential for custom ligand solutions and affinity resins.

Digital Engagement With a tech stack incorporating platforms like HubSpot and Calendly, Navigo actively manages client interactions and sales processes, providing a solid foundation for outreach and engagement. This indicates readiness to scale B2B sales efforts through targeted marketing and personalized communications toward pharma and biotech companies.